(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.
The three biggest winners today are Xenetic Biosciences, U.S. Gold Corp, and MicroStrategy.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Xenetic Biosciences (XBIO) | 3.26 | 3.91% | 2023-07-04 04:15:47 |
| 2 | U.S. Gold Corp (USAU) | 4.45 | 3.25% | 2023-07-04 04:15:42 |
| 3 | MicroStrategy (MSTR) | 388.00 | 2.69% | 2023-07-04 04:11:16 |
| 4 | Aurora Cannabis (ACB) | 0.60 | 2.67% | 2023-07-04 04:46:55 |
| 5 | Clean Energy Fuels (CLNE) | 4.95 | 2.48% | 2023-07-04 04:08:30 |
| 6 | Riot Blockchain (RIOT) | 13.64 | 2.17% | 2023-07-04 04:15:03 |
| 7 | Fidelity National Information Services (FIS) | 59.25 | 2.16% | 2023-07-04 04:18:16 |
| 8 | Vertex Pharmaceuticals (VRTX) | 355.05 | 2.15% | 2023-07-04 04:36:24 |
| 9 | Marathon (MARA) | 15.64 | 2.09% | 2023-07-04 04:11:00 |
| 10 | Identiv (INVE) | 8.96 | 1.93% | 2023-07-04 04:10:39 |
The three biggest losers today are Upland Software, TherapeuticsMD, and Banco Santander.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Upland Software (UPLD) | 3.57 | -4.02% | 2023-07-04 07:28:46 |
| 2 | TherapeuticsMD (TXMD) | 4.02 | -3.83% | 2023-07-04 04:15:35 |
| 3 | Banco Santander (SAN) | 3.61 | -3.73% | 2023-07-04 04:44:18 |
| 4 | NeuroMetrix (NURO) | 0.95 | -2.74% | 2023-07-04 04:35:57 |
| 5 | FuboTV (FUBO) | 2.20 | -2.22% | 2023-07-04 04:46:42 |
| 6 | VerifyMe (VRME) | 1.35 | -2.18% | 2023-07-04 04:37:09 |
| 7 | Groupon (GRPN) | 6.08 | -1.94% | 2023-07-04 04:10:08 |
| 8 | BioNTech SE (BNTX) | 105.90 | -1.78% | 2023-07-04 04:36:33 |
| 9 | Quidel (QDEL) | 81.83 | -1.71% | 2023-07-04 04:12:00 |
| 10 | NRG Energy (NRG) | 37.13 | -1.3% | 2023-07-04 04:43:00 |
Premarket Winners today
1. Xenetic Biosciences (XBIO) – Premarket: 3.91%
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
NASDAQ ended the session with Xenetic Biosciences dropping 0.72% to $3.14 on Tuesday, following the last session’s downward trend. NASDAQ rose 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-3.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.06%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 40.5% and a drop 86.7% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xenetic Biosciences’s EBITDA is 7.58.
Sales Growth
Xenetic Biosciences’s sales growth is 5.5% for the present quarter and 15.9% for the next.
More news about Xenetic Biosciences.
2. U.S. Gold Corp (USAU) – Premarket: 3.25%
U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 650 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 87 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project that consists of 103 unpatented mining claims covering approximately 3 square miles in Eureka County, Nevada. The company is based in Elko, Nevada.
NASDAQ ended the session with U.S. Gold Corp dropping 3.15% to $4.31 on Tuesday, after two consecutive sessions in a row of losses. NASDAQ jumped 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-0.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.37%.
Moving Average
U.S. Gold Corp’s value is above its 50-day moving average of $4.22 and higher than its 200-day moving average of $4.29.
Yearly Top and Bottom Value
U.S. Gold Corp’s stock is valued at $4.31 at 08:34 EST, way below its 52-week high of $7.48 and way above its 52-week low of $3.50.
More news about U.S. Gold Corp.
3. MicroStrategy (MSTR) – Premarket: 2.69%
MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.
NASDAQ ended the session with MicroStrategy jumping 10.34% to $377.84 on Tuesday, after five successive sessions in a row of gains. NASDAQ rose 0.21% to $13,816.77, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, MicroStrategy has a trailing twelve months EPS of $-85.35.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.41%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.2%, now sitting on 501.9M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MicroStrategy’s EBITDA is 234.79.
More news about MicroStrategy.
4. Aurora Cannabis (ACB) – Premarket: 2.67%
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.
NYSE ended the session with Aurora Cannabis jumping 8.51% to $0.58 on Tuesday, after two sequential sessions in a row of gains. NYSE rose 0.27% to $15,918.50, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.91.
Sales Growth
Aurora Cannabis’s sales growth is 27.3% for the present quarter and 23.5% for the next.
Volume
Today’s last reported volume for Aurora Cannabis is 4552150 which is 42.35% above its average volume of 3197830.
Volatility
Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was 0.13%, 0.19%, and 2.98%.
Aurora Cannabis’s highest amplitude of average volatility was 0.93% (last week), 3.35% (last month), and 2.98% (last quarter).
More news about Aurora Cannabis.
5. Clean Energy Fuels (CLNE) – Premarket: 2.48%
Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2022, the company served approximately 1,000 fleet customers operating approximately 50,000 vehicles. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
NASDAQ ended the session with Clean Energy Fuels sliding 2.62% to $4.83 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Clean Energy Fuels has a trailing twelve months EPS of $-0.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.24%.
Sales Growth
Clean Energy Fuels’s sales growth is 7.4% for the present quarter and negative 13.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 58.3%, now sitting on 468.85M for the twelve trailing months.
Yearly Top and Bottom Value
Clean Energy Fuels’s stock is valued at $4.83 at 08:34 EST, way below its 52-week high of $8.58 and way higher than its 52-week low of $3.84.
More news about Clean Energy Fuels.
6. Riot Blockchain (RIOT) – Premarket: 2.17%
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
NASDAQ ended the session with Riot Blockchain jumping 12.94% to $13.35 on Tuesday, after three consecutive sessions in a row of gains. NASDAQ rose 0.21% to $13,816.77, after two sequential sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-4.29.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 252.62M for the twelve trailing months.
Volatility
Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was 3.60%, 0.69%, and 5.07%.
Riot Blockchain’s highest amplitude of average volatility was 4.08% (last week), 3.95% (last month), and 5.07% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Riot Blockchain’s EBITDA is -683.8.
Volume
Today’s last reported volume for Riot Blockchain is 28901200 which is 25.45% above its average volume of 23037200.
More news about Riot Blockchain.
7. Fidelity National Information Services (FIS) – Premarket: 2.16%
Fidelity National Information Services, Inc. provides technology solutions for financial institutions and businesses worldwide. It operates through Banking Solutions, Merchant Solutions, and Capital Market Solutions segments. The Banking Solutions segment provides core processing and ancillary applications; mobile and online banking; fraud, risk management, and compliance; electronic funds transfer and network; card and retail payment; wealth and retirement; and item processing and output solutions. The Merchant Solutions segment offers small- to medium-sized businesses acquiring, enterprise acquiring, and ecommerce solutions. The Capital Market Solutions segment provides investment operations and data, lending, trading and processing, and treasury and risk solutions. The company was founded in 1968 and is headquartered in Jacksonville, Florida.
NYSE ended the session with Fidelity National Information Services rising 6.03% to $58.00 on Tuesday while NYSE rose 0.27% to $15,918.50.
Earnings Per Share
As for profitability, Fidelity National Information Services has a trailing twelve months EPS of $-27.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.91%.
Volatility
Fidelity National Information Services’s last week, last month’s, and last quarter’s current intraday variation average was 2.10%, 0.09%, and 1.53%.
Fidelity National Information Services’s highest amplitude of average volatility was 2.29% (last week), 1.07% (last month), and 1.53% (last quarter).
Sales Growth
Fidelity National Information Services’s sales growth is negative 0.3% for the current quarter and negative 0.6% for the next.
Volume
Today’s last reported volume for Fidelity National Information Services is 8649020 which is 71.21% above its average volume of 5051540.
More news about Fidelity National Information Services.
8. Vertex Pharmaceuticals (VRTX) – Premarket: 2.15%
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
NASDAQ ended the session with Vertex Pharmaceuticals falling 1.23% to $347.57 on Tuesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.53.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 27.74. Meaning, the purchaser of the share is investing $27.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.73%.
Moving Average
Vertex Pharmaceuticals’s value is higher than its 50-day moving average of $339.86 and way above its 200-day moving average of $312.03.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 10.3% for the present quarter and 10.4% for the next.
Yearly Top and Bottom Value
Vertex Pharmaceuticals’s stock is valued at $347.57 at 08:34 EST, under its 52-week high of $354.94 and way higher than its 52-week low of $271.61.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Vertex Pharmaceuticals’s stock is considered to be overbought (>=80).
More news about Vertex Pharmaceuticals.
9. Marathon (MARA) – Premarket: 2.09%
Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
NASDAQ ended the session with Marathon jumping 10.53% to $15.32 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Marathon has a trailing twelve months EPS of $-6.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 117.16M for the twelve trailing months.
More news about Marathon.
10. Identiv (INVE) – Premarket: 1.93%
Identiv, Inc. operates as a security technology company that secures things, data, and physical places in the Americas, Europe, the Middle East, and the Asia-Pacific. The company operates in two segments, Identity and Premises. The Identity segment offers products and solutions that enables secure access to information serving the logical access and cyber security markets, as well as protecting connected objects and information using radio-frequency identification embedded security. The Premises segment provides solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, and apartment buildings. The company sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.
NASDAQ ended the session with Identiv rising 4.52% to $8.79 on Tuesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Identiv has a trailing twelve months EPS of $-0.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.87%.
Moving Average
Identiv’s worth is way above its 50-day moving average of $6.96 and higher than its 200-day moving average of $8.28.
More news about Identiv.
Premarket Losers Today
1. Upland Software (UPLD) – Premarket: -4.02%
Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.
NASDAQ ended the session with Upland Software jumping 3.33% to $3.72 on Tuesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Upland Software has a trailing twelve months EPS of $-6.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.96%.
Moving Average
Upland Software’s value is way higher than its 50-day moving average of $3.36 and way below its 200-day moving average of $6.29.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Upland Software’s EBITDA is 1.53.
More news about Upland Software.
2. TherapeuticsMD (TXMD) – Premarket: -3.83%
TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
NASDAQ ended the session with TherapeuticsMD rising 1.46% to $4.18 on Tuesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $1.93.
PE Ratio
TherapeuticsMD has a trailing twelve months price to earnings ratio of 2.17. Meaning, the purchaser of the share is investing $2.17 for every dollar of annual earnings.
Yearly Top and Bottom Value
TherapeuticsMD’s stock is valued at $4.18 at 08:34 EST, way below its 52-week high of $11.69 and way higher than its 52-week low of $3.25.
Volatility
TherapeuticsMD’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.12%, a negative 0.30%, and a positive 2.66%.
TherapeuticsMD’s highest amplitude of average volatility was 1.76% (last week), 2.09% (last month), and 2.66% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 40.1%, now sitting on 69.68M for the twelve trailing months.
More news about TherapeuticsMD.
3. Banco Santander (SAN) – Premarket: -3.73%
Banco Santander, S.A. provides various retail and commercial banking products and services to individuals, small and medium-sized enterprises, and large companies worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, and current and savings accounts; mortgages, consumer finance, syndicated corporate loans, cash management, export and agency finance, trade and working capital solutions, and corporate finance; and insurance products. The company also provides cash, asset, and wealth management; and private banking services. In addition, it is involved in the corporate banking, treasury, risk hedging, foreign trade, and investment banking activities, as well as provides digital payment solutions. The company was formerly known as Banco Santander Central Hispano S.A. and changed its name to Banco Santander, S.A. in June 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.
NYSE ended the session with Banco Santander rising 1.08% to $3.75 on Tuesday, after five consecutive sessions in a row of gains. NYSE rose 0.27% to $15,918.50, after three consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Banco Santander has a trailing twelve months EPS of $0.6.
PE Ratio
Banco Santander has a trailing twelve months price to earnings ratio of 6.25. Meaning, the purchaser of the share is investing $6.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.82%.
Yearly Top and Bottom Value
Banco Santander’s stock is valued at $3.75 at 08:34 EST, under its 52-week high of $4.09 and way higher than its 52-week low of $2.26.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Banco Santander’s stock is considered to be oversold (<=20).
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 26, 2023, the estimated forward annual dividend rate is 0.12 and the estimated forward annual dividend yield is 3.45%.
More news about Banco Santander.
4. NeuroMetrix (NURO) – Premarket: -2.74%
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ ended the session with NeuroMetrix rising 0.25% to $0.98 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.61.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.76%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
NeuroMetrix’s EBITDA is 5.5.
Moving Average
NeuroMetrix’s worth is under its 50-day moving average of $1.09 and way below its 200-day moving average of $1.64.
Revenue Growth
Year-on-year quarterly revenue growth declined by 25.1%, now sitting on 7.68M for the twelve trailing months.
More news about NeuroMetrix.
5. FuboTV (FUBO) – Premarket: -2.22%
fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.
NYSE ended the session with FuboTV jumping 8.17% to $2.25 on Tuesday, after two successive sessions in a row of gains. NYSE rose 0.27% to $15,918.50, after three sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, FuboTV has a trailing twelve months EPS of $-1.91.
Volatility
FuboTV’s last week, last month’s, and last quarter’s current intraday variation average was 2.21%, 1.21%, and 5.86%.
FuboTV’s highest amplitude of average volatility was 2.53% (last week), 4.14% (last month), and 5.86% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 52.4% and 56.1%, respectively.
Sales Growth
FuboTV’s sales growth is 36.2% for the present quarter and 38.7% for the next.
More news about FuboTV.
6. VerifyMe (VRME) – Premarket: -2.18%
VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.
NASDAQ ended the session with VerifyMe dropping 0% to $1.38 on Tuesday, after two sequential sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, VerifyMe has a trailing twelve months EPS of $-1.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -88%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VerifyMe’s EBITDA is -11.23.
Yearly Top and Bottom Value
VerifyMe’s stock is valued at $1.38 at 08:34 EST, way below its 52-week high of $2.46 and way higher than its 52-week low of $1.01.
More news about VerifyMe.
7. Groupon (GRPN) – Premarket: -1.94%
Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Groupon jumping 4.91% to $6.20 on Tuesday while NASDAQ jumped 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Groupon has a trailing twelve months EPS of $-7.76.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -285.15%.
Yearly Top and Bottom Value
Groupon’s stock is valued at $6.20 at 08:34 EST, way below its 52-week high of $14.85 and way above its 52-week low of $2.89.
Moving Average
Groupon’s value is way higher than its 50-day moving average of $4.54 and under its 200-day moving average of $6.59.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Groupon’s EBITDA is -26.49.
More news about Groupon.
8. BioNTech SE (BNTX) – Premarket: -1.78%
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
NASDAQ ended the session with BioNTech SE sliding 0.1% to $107.82 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.21% to $13,816.77, after two successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, BioNTech SE has a trailing twelve months EPS of $28.06.
PE Ratio
BioNTech SE has a trailing twelve months price to earnings ratio of 3.84. Meaning, the purchaser of the share is investing $3.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.49%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BioNTech SE’s stock is considered to be oversold (<=20).
More news about BioNTech SE.
9. Quidel (QDEL) – Premarket: -1.71%
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
NASDAQ ended the session with Quidel rising 0.47% to $83.25 on Tuesday while NASDAQ rose 0.21% to $13,816.77.
Earnings Per Share
As for profitability, Quidel has a trailing twelve months EPS of $-1.03.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.17%.
More news about Quidel.
10. NRG Energy (NRG) – Premarket: -1.3%
NRG Energy, Inc., together with its subsidiaries, operates as an integrated power company in the United States. It operates through Texas, East, and West segments. The company is involved in producing and selling electricity and related products and services to approximately residential, commercial, industrial, and wholesale customers. It generates electricity using natural gas, coal, oil, solar, nuclear, and battery storage. The company also provides system power, distributed generation, renewable products, backup generation, storage and distributed solar, demand response, and energy efficiency and advisory services, as well as carbon management and specialty services. In addition, it trades in electric power, natural gas, and related commodities; environmental products; weather products; and financial products, including forwards, futures, options, and swaps. Further, the company procures fuels; and sells energy, services, and products and services under the NRG, Reliant, Direct Energy, Green Mountain Energy, Stream, and XOOM Energy. NRG Energy, Inc. was founded in 1989 and is headquartered in Houston, Texas.
NYSE ended the session with NRG Energy jumping 0.62% to $37.62 on Tuesday, after three successive sessions in a row of gains. NYSE rose 0.27% to $15,918.50, after three successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, NRG Energy has a trailing twelve months EPS of $-7.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.62%.
Moving Average
NRG Energy’s value is way higher than its 50-day moving average of $33.85 and above its 200-day moving average of $35.99.
Volatility
NRG Energy’s last week, last month’s, and last quarter’s current intraday variation average was 0.73%, 0.62%, and 1.33%.
NRG Energy’s highest amplitude of average volatility was 0.78% (last week), 1.12% (last month), and 1.33% (last quarter).
More news about NRG Energy.
Stay up to date with our premarket winners and losers daily report
